Immunotherapy duo takes on rare childhood tumors

NCT ID NCT04416568

First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 32 times

Summary

This study tests whether combining two immunotherapy drugs, nivolumab and ipilimumab, can shrink or control rare INI1-negative cancers in children and young adults. These cancers have returned or not responded to standard treatments. The goal is to see if the drug combo helps the immune system fight the tumors more effectively.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Children's Healthcare of Atlanta-Egleston

    Atlanta, Georgia, 30322, United States

  • Children's Healthcare of Atlanta-Scottish Rite

    Atlanta, Georgia, 30342, United States

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Texas Children's Hospital

    Houston, Texas, 77030, United States

  • UCSF Benioff Children's Hospital

    San Francisco, California, 94158, United States

Conditions

Explore the condition pages connected to this study.